US Patent

US7151103 — Method of treating female hypoactive sexual desire disorder with flibanserin

Method of Use · Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2028-05-09 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of flibanserin for treating female hypoactive sexual desire disorder.

USPTO Abstract

The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.

Drugs covered by this patent

Addyi (FLIBANSERIN) · Sprout Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1734`	—	Addyi

Patent Metadata

Patent number: US7151103
Jurisdiction: US
Classification: Method of Use
Expires: 2028-05-09
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim Pharma GmbH and Co KG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.